Physician profile
May M San
NPI 1619393105
$1,597.27
in general payments reported to CMS, 2019-2025
16 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $597 · 2022: $248 · 2023: $325 · 2024: $322 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $658 · Education: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $657.54 |
| Education | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $346.05 | 2021-2024 | Reblozyl |
| Astellas Pharma US INC | $275.48 | 2021-2025 | Vyloy, Xospata |
| Abbvie INC. | $166.32 | 2021-2025 | |
| Epizyme, INC. | $99.99 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.09 | 2021-2024 | Ninlaro, Iclusig |
| Sanofi-Aventis U.S. LLC | $83.00 | 2022 | |
| Genentech USA, INC. | $82.83 | 2023-2024 | Venclexta, Polivy |
| Amgen INC. | $80.72 | 2021-2023 | Kyprolis |
| Incyte Corporation | $79.52 | 2021-2024 | Pemazyre, Monjuvi |
| Novartis Pharmaceuticals Corporation | $77.14 | 2023 | |
| Genzyme Corporation | $61.13 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $46.53 | 2023-2024 | Dificid, Prevymis |
| Pfizer INC. | $38.01 | 2025 | |
| Jazz Pharmaceuticals INC. | $24.32 | 2021 | |
| Alexion Pharmaceuticals, INC. | $20.44 | 2023 | Ultomiris |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $19.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw May San listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.